Fig. 6
RORγt agonist promotes CCL20-CCR6 signaling and enhances Type 17 T cell migration. a Relative cytokine level of CCL20 in the LLC tumors and the MC38 tumor from the vehicle or 8-074 treated ELISA analyzed mice (*P < 0.05). b Transwell assay of the CCL20-CCR6 mediated Mo-DC migration. Statistical result of the migrated cells in the bottom chamber was shown (N = 3, ***P < 0.001). c and d Validation of the CCL20-CCR6 mediated Transwell migration assay. 1 × 105 Th17 cells (c) or Tc17 cells (d) were added to the upper chamber. The lower chamber contained medium alone (-), or medium with recombinant CCL20, neutralizing anti-(α) CCL20 mAb, neutralizing anti-CCR6 mAb. The migrated cells in the lower chamber were counted after 3 h or 6 h. (*P < 0.05; **P < 0.01; ***P < 0.001 and ****P < 0.001). e Representative flow cytometry graph for the analysis of CCR6 in Th17 cells. f Statistical results of FCM analysis for CCR6+ IL-17A+ cells among the CD4+ T cells in Fig. 6e. A Student’s t-test was used for determining significance (***P < 0.001). g Representative flow panels of the analysis of CCR6 in Tc17 cells. h Statistical results of FCM analysis for CCR6+ IL-17A+ cells among the CD4+ T cells in Fig. 6g. A Student’s t-test was used for determining significance (**P < 0.01, ***P < 0.001). The student’s t-test was used for the statistical test. Data represent mean ± SD of biological quadruplicates. Experiments were repeated three times with consistent results